By: IPP Bureau
Last updated : August 14, 2026 6:15 pm
Sapra’s tenure to be effective November 16, 2026, bringing 27 years of pharmaceutical leadership across CDMO, generics and global business development
Gland Pharma Limited has announced the appointment of Mr. Deepak Sapra as its new Chief Executive Officer, effective from November 16, 2026.
The appointment follows the recommendation of the Nomination and Remuneration Committee and approval by the company's Board, and remains subject to Sapra's acceptance of the offer.
Sapra brings 27 years of executive experience, including more than 23 years in the pharmaceutical industry. He currently serves as Chief Executive Officer – API and Services at Dr. Reddy's Laboratories Limited (DRL) and as a Board Member of Aurigene Pharma Services.
In his current role, Sapra oversees global portfolio strategy and leads an integrated B2B business spanning generic pharmaceuticals, CDMO services, APIs, collaborations and alliances, public health, and global patient access, with operations across major markets including the United States, the European Union, Japan, Brazil, China, Mexico, the Middle East and emerging markets in Africa.
He has built a track record of driving revenue growth, market expansion and entry, business development, licensing, M&A and portfolio creation across India, the United States, Europe, Latin America, Africa, the Middle East, China, Japan and the wider Asia-Pacific region.
His experience spans the end-to-end pharmaceutical value chain, including CDMO partnerships, generics, APIs, sales and marketing, international business management, business development, supply chain management, R&D, operations, portfolio strategy, and public health and access-led partnerships.
Prior to his current role, Sapra served as Chief Executive Officer – Custom Pharmaceutical Services, leading a global CDMO business serving innovator pharmaceutical companies across the United States, Europe and Japan. Between 2011 and 2015, he held senior leadership roles as Vice President – Global Generics Business Development and Senior Director – Global Generics Portfolio Management.
The appointment was disclosed by Gland Pharma in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.